For: | Butt MI, Khalid Bakhsh AM, Nadri QJ. Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report. World J Clin Oncol 2021; 12(4): 272-281 [PMID: 33959480 DOI: 10.5306/wjco.v12.i4.272] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v12/i4/272.htm |
Number | Citing Articles |
1 |
Young Kee Shong. Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer. International Journal of Thyroidology 2021; 14(2): 98 doi: 10.11106/ijt.2021.14.2.98
|
2 |
Tomohiro Enokida, Makoto Tahara. Management of VEGFR-Targeted TKI for Thyroid Cancer. Cancers 2021; 13(21): 5536 doi: 10.3390/cancers13215536
|
3 |
Tingting Ren, Tao Zhong, Fuhua Yang, Xuesong Liao, Mei Yang, Lingling Ji, Zonglin Guo, Jun Huang. Immune Reconstitution After Total Parathyroidectomy and Forearm Transplantation in Chronic Renal Failure. Journal of Craniofacial Surgery 2024; doi: 10.1097/SCS.0000000000010713
|